FDA: Page
-
Deep Dive
ICYMI: India's fixed-dose combo problem: Too much of a good thing?
Change is brewing in Indian pharma. But will it be enough?
By Nicole Gray • Nov. 14, 2014 -
Indian pharma really feeling the pain of lagging US generic approvals
Increased filings for new generic drugs, combined with increased inspections of Indian facilities beset by quality woes, has led to a severe revenue slowdown in India.
By Nicole Gray • Nov. 13, 2014 -
GSK applying for expanded Revolade indication in the EU
If GSK gets its way, Revoldate (eltrombopag) will be available in the EU for the treatment of severe aplastic anemia (SAA) in addition to its primary indication, thrombocytopenia.
By Nicole Gray • Nov. 13, 2014 -
No more half measures: Senate to add Ebola to priority review program
Next week, the Senate will consider making Ebola the 17th tropical disease target eligible for priority review. And other big changes to the program are coming, too.
By Nicole Gray • Nov. 13, 2014 -
10 major hospitals ask Congress to scrutinize Genentech distribution changes
In October, Ascension Health banned Genentech sales reps from its campus in response to a radical shift in distribution policy. Now, other major medical centers are piling on.
By Nicole Gray • Nov. 12, 2014 -
Specter of antitrust charges looms as Justice Department probes generic price hikes
Over the last year, the cost of generic drugs has tripled for some patients.
By Sy Mukherjee • Nov. 11, 2014 -
Pfizer: Nothing shady about our relationship with Missouri Attorney General
Pfizer has written to the NYT denying all allegations of wrong-doing after the paper published a piece last month claiming unethical communications between the company and Missouri AG Chris Koster.
By Nicole Gray • Nov. 11, 2014 -
Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug
The FDA will make a decision about Amgen's evolocumab by next August. But will someone beat Amgen to the PCSK9 party?
By Nicole Gray • Nov. 11, 2014 -
FDA
FDA sends Sciecure Pharma rare, scathing letter over insomnia drug sales aid
The FDA's OPDP sent a letter to Sciecure Pharma about a sales aid for its insomnia drug Doral (quazepam), citing a lack of risk disclosure.
By Nicole Gray • Nov. 7, 2014 -
Ranbaxy loses $250M while US consumers lose a Nexium generic
The FDA yanked tentative approval of generic versions of Roche's Valcyte and AZ's Nexium manufactured by Indian firm Ranbaxy Laboratories on Thursday. It could be a hefty financial blow.
By Nicole Gray • Nov. 7, 2014 -
FDA approves JNJ's Olysio in combo with Sovadi for hep C treatment
There are now two all-oral treatment options for hepatitis C patients.
By Nicole Gray • Nov. 7, 2014 -
UPDATED: Novartis cancer hopeful panobinostat not on track for FDA approval
Panobinostat, which Novartis developed as part of a combo therapy for multiple myeloma, did not show superiority in clinical trials—and it was associated with an increased risk of death.
By Nicole Gray • Nov. 6, 2014 -
Some payments exempt from Sunshine Act pharma database reporting
The Obama admin has decided that in certain cases, companies don't have to report payments to physicians who participate in CME events, especially if they're funded by non-commercial sources.
By Nicole Gray • Nov. 5, 2014 -
India-based Wockhardt's profits plummet as it faces continued FDA export ban
Indian exports have dropped by 90% compared with 2012 since last year's export ban, which probably won't be lifted until at least next year. But Wockhardt's stock is up 70% this year on buy-out rumors.
By Nicole Gray • Nov. 4, 2014 -
Will Boehringer win an asthma indication for Spiriva Respimat?
If approved, Spiriva Respimat Inhalation Spray will provide asthma patients with another treatment option—and be the first new approved inhaled therapy for asthma patients in over a decade.
By Nicole Gray • Nov. 4, 2014 -
Feds probe whether US officials engaged in insider trading over Dendreon drug
The SEC is aggressively investigating insider trading allegations that date back to 2010 and center on a review of Dendreon's prostate cancer drug, Provenge.
By Nicole Gray • Nov. 3, 2014 -
Uh-oh: 2/3 of UK docs defying new statin guidelines
The controversial and aggressive new statin guidelines continue to expose rifts within the medical community.
By Sy Mukherjee • Nov. 3, 2014 -
Express Scripts gearing up to snub Gilead in favor of AbbVie hep C drug
Express Scripts' medical chief made it clear last week that the company's looking for an HCV treatment that is as effective as Gilead's Sovaldi (sofosbuvir)—but cheaper.
By Nicole Gray • Nov. 3, 2014 -
FDA panel endorses approval of Daaichi's blood clot, stroke drug
If approved, edoxaban, a once-daily factor Xa inhibitor, will become the third FXa inhibitor available in the U.S.—and it may become the biggest seller in its class, according to experts.
By Nicole Gray • Nov. 3, 2014 -
Pfizer's meningitis drug becomes first FDA-approved breakthrough therapy
Trumenba, Pfizer's meningococcal group B vaccine, was approved by the FDA's Center for Biologics Evaluation and Research (CBER) after an expedited four-month review.
By Nicole Gray • Oct. 31, 2014 -
AZ scores FDA approval of once-daily diabetes fixed-dose combo pill
Xigduo XR is the first once-daily fixed-dose combination of an SGLT2 inhibitor (Farxiga/dapagliflozin) and metformin to win FDA approval.
By Sy Mukherjee • Oct. 30, 2014 -
US senators propose FDA vouchers to expedite Ebola drug development
Lawmakers have proposed a voucher system that would give drug developers an expedited review in order to encourage the creation of as many Ebola treatments as possible.
By Nicole Gray • Oct. 30, 2014 -
Deep Dive
Diving into the future of fixed-dose combos
From respiratory disease to HIV therapeutics, fixed-dose combinations are an important part of drug development. The regulatory hurdles are high—but so are the rewards.
By Nicole Gray • Oct. 30, 2014 -
India to ban use of plastic bottles for liquid drugs
Drug manufacturers aren't pleased with the decision.
By Nicole Gray • Oct. 30, 2014 -
Feds announce new Ebola guidelines
The new guidelines establish four tiers of risk.
By Katie Bo Williams • Oct. 29, 2014
Previous
